SI1505973T1 - Kombinacija za zdravljenje multiplega mieloma - Google Patents

Kombinacija za zdravljenje multiplega mieloma

Info

Publication number: SI1505973T1
Authority: SI; Slovenia
Prior art keywords: methods; administration; disclosed; therapy; combinations
Prior art date: 2002-05-17

Application number

SI200331793T

Other languages

English (en)

Inventor

Jerome B Zeldis

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-17

Filing date

2003-05-16

Publication date

2010-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29553516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1505973(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-05-16 Application filed by Celgene Corp filed Critical Celgene Corp

2010-06-30 Publication of SI1505973T1 publication Critical patent/SI1505973T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Oncology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Virology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Tropical Medicine & Parasitology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Addiction (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)

SI200331793T 2002-05-17 2003-05-16 Kombinacija za zdravljenje multiplega mieloma SI1505973T1 (sl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US38084202P	2002-05-17	2002-05-17
US42460002P	2002-11-06	2002-11-06
PCT/US2003/015470 WO2003097052A2 (en)	2002-05-17	2003-05-16	Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
EP03728969A EP1505973B1 (en)	2002-05-17	2003-05-16	Combinations for treating multiple myeloma

Publications (1)

Publication Number	Publication Date
SI1505973T1 true SI1505973T1 (sl)	2010-06-30

Family

ID=29553516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200331793T SI1505973T1 (sl)	2002-05-17	2003-05-16	Kombinacija za zdravljenje multiplega mieloma

Country Status (19)

Country	Link
EP (9)	EP2087891A3 (sl)
JP (8)	JP2005530784A (sl)
KR (2)	KR100793564B1 (sl)
CN (13)	CN102302494A (sl)
AT (1)	ATE459357T1 (sl)
AU (1)	AU2003234626B2 (sl)
CA (10)	CA2752140A1 (sl)
CY (3)	CY1110013T1 (sl)
DE (1)	DE60331537D1 (sl)
DK (1)	DK1505973T3 (sl)
ES (2)	ES2521672T3 (sl)
IL (9)	IL165254A0 (sl)
LU (1)	LU92642I2 (sl)
MX (1)	MXPA04011311A (sl)
NZ (5)	NZ563281A (sl)
PT (2)	PT1505973E (sl)
SI (1)	SI1505973T1 (sl)
WO (1)	WO2003097052A2 (sl)
ZA (3)	ZA200503656B (sl)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
ES2338534T3 (es)	2001-02-27	2010-05-10	The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services	Analogos de talidomina como inhibidores de la angiogenesis.
US7393862B2 (en) *	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CA2752140A1 (en)	2002-05-17	2003-11-27	Celgene Corporation	Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en)	2002-10-15	2007-03-13	Celgene Corporation	Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
NZ540186A (en) *	2002-10-31	2008-03-28	Celgene Corp	Composition for the treatment of macular degeneration
US7785601B2 (en) *	2002-12-31	2010-08-31	Sygnis Bioscience Gmbh & Co. Kg	Methods of treating neurological conditions with hematopoietic growth factors
WO2005016326A2 (en) *	2003-07-11	2005-02-24	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Analogs of thalidomide as potential angiogenesis inhibitors
UA83504C2 (en)	2003-09-04	2008-07-25	Селджин Корпорейшн	Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US8952895B2 (en)	2011-06-03	2015-02-10	Apple Inc.	Motion-based device operations
US7973057B2 (en)	2003-09-17	2011-07-05	The United States Of America As Represented By The Department Of Health And Human Services	Thalidomide analogs
US20050100529A1 (en) *	2003-11-06	2005-05-12	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
KR20060109979A (ko) *	2003-12-02	2006-10-23	셀진 코포레이션	혈색소병증　및　빈혈의　치료　및　관리를　위한　방법및　조성물
US20050143344A1 (en) *	2003-12-30	2005-06-30	Zeldis Jerome B.	Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
CA2601278C (en)	2004-03-17	2014-06-10	Lars Michael Larsen	Prevention of retinopathy by inhibition of the visual cycle
KR101224262B1 (ko) *	2004-03-22	2013-01-21	셀진 코포레이션	면역조절 화합물을 포함하는 피부 질환 또는 장애의 치료및 관리용 조성물 및 이의 사용 방법
KR101164696B1 (ko) *	2004-04-14	2012-07-11	셀진 코포레이션	골수이형성 증후군의 치료 및 관리를 위한 면역조절화합물의 사용 방법 및 상기 화합물을 포함하는 조성물
KR20070086000A (ko) *	2004-11-12	2007-08-27	셀진 코포레이션	기생충성 질병의 치료 및 관리를 위한 면역조절성 화합물을사용하는 방법 및 조성물
EP1827431A1 (en) *	2004-11-23	2007-09-05	Celgene Corporation	Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
EP1928492B1 (en) *	2005-09-01	2011-02-23	Celgene Corporation	Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
JP5984324B2 (ja) *	2005-12-01	2016-09-06	メディカルプログノシスインスティテュートエー／エス	治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用
CA2648216C (en)	2006-04-13	2016-06-07	Michael Gutschow	Tetrahalogenated compounds useful as inhibitors of angiogenesis
JP2009538318A (ja) *	2006-05-26	2009-11-05	セルジーン・コーポレーション	併用療法において免疫調節化合物を用いる方法及び組成物
CL2007002218A1 (es)	2006-08-03	2008-03-14	Celgene Corp Soc Organizada Ba	Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
HUE029027T2 (en) *	2006-08-07	2017-01-30	Abbvie Biotherapeutics Inc	Procedures for Multiple Myeloma Treatment Using HuLuc63 and Bortezomib Combination Therapies
CN101557806A (zh) *	2006-10-19	2009-10-14	细胞基因公司	使用免疫调节化合物治疗和控制螺旋体和其它专性胞内菌疾病的方法和组合物
RU2348420C2 (ru) *	2007-04-17	2009-03-10	ФГУ Ростовский научно-исследовательский онкологический институт Росздрава	Способ лечения местно-распространенного рака легкого
AU2008307633C1 (en) *	2007-09-28	2015-04-30	Celularity Inc.	Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
UA104579C2 (uk)	2007-12-10	2014-02-25	Байокрист Фармасьютикалз, Инк.	Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом
CA2712724A1 (en) *	2008-01-29	2009-08-06	Celgene Corporation	Use of lenalidomide or pomalidomide for treating a disease associated with cd59 deficiency
RU2398525C1 (ru) *	2009-03-25	2010-09-10	Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий"	Способ лечения рака легкого
CN101696205B (zh)	2009-11-02	2011-10-19	南京卡文迪许生物工程技术有限公司	3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
CA2780998C (en) *	2009-11-24	2016-07-12	Celgene Corporation	Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells
SG10201501062SA (en)	2010-02-11	2015-04-29	Celgene Corp	Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
EP2544687A1 (en) *	2010-03-12	2013-01-16	Celgene Corporation	Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
US10426740B1 (en)	2010-08-18	2019-10-01	Avm Biotechnology, Llc	Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
AU2011291651B2 (en) *	2010-08-18	2016-01-14	Avm Biotechnology, Llc	Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
WO2012062366A1 (en) *	2010-11-11	2012-05-18	Ingo Schmidt-Wolf	Compositions comprising wnt inhibitors for treating cancer
US8927725B2 (en)	2011-12-02	2015-01-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Thio compounds
CN104797256A (zh) *	2012-09-10	2015-07-22	细胞基因公司	用于治疗局部晚期乳腺癌的方法
EA201591902A1 (ru) *	2013-04-02	2016-02-29	Селджин Корпорейшн	Способы и композиции, использующие 4-амино-2-(2,6-диоксо-пиперидин-3-ил)изоиндолин-1,3-дион для лечения и контроля злокачественных опухолей центральной нервной системы
GB201322626D0 (en)	2013-12-19	2014-02-05	Immutep S A	Combined preparations for the treatment of cancer
CN104231068A (zh) *	2014-01-27	2014-12-24	苏州发士达生物科技有限公司	人白细胞介素ii突变体及其应用
JP6616934B2 (ja) *	2014-05-22	2019-12-04	株式会社資生堂	レナリドミドの光学分割方法
LT3182996T (lt)	2014-08-22	2023-03-10	Celgene Corporation	Daugybinės mielomos gydymo būdai imunomoduliuojančiais junginiais derinyje su antikūnais
FI3198035T3 (fi)	2014-09-26	2023-01-31		Menetelmiä lääkevasteen ennustamiseksi
GB201500374D0 (en)	2015-01-09	2015-02-25	Immutep S A	Combined preparations for the treatment of cancer
SG11201705783WA (en) *	2015-01-20	2017-08-30	Sreevatsan Raghavan	Self-illuminating cheek retractor
CN108366987A (zh) *	2015-04-30	2018-08-03	河谷控股Ip有限责任公司	通过致畸药物化合物对患者进行治疗
ES2886657T3 (es) *	2015-06-29	2021-12-20	Bristol Myers Squibb Co	Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer
KR20180086195A (ko) *	2015-10-21	2018-07-30	테크리슨 리미티드	면역 매개 암 치료를 위한 조성물 및 방법
CN105388237B (zh) *	2015-12-28	2017-02-01	成都百裕金阁莱药业有限公司	阿普斯特中3‑乙酰氨基邻苯二甲酸的检测方法
US9725769B1 (en)	2016-10-07	2017-08-08	Oncology Venture ApS	Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en)	2016-12-30	2018-07-19	Allarity Therapeutics Europe ApS	Methods for predicting drug responsiveness in cancer patients
EP3577109A4 (en)	2017-01-31	2020-11-18	Arvinas Operations, Inc.	CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
ES2954311T3 (es)	2017-04-01	2023-11-21	Avm Biotechnology Llc	Reemplazo de un preacondicionamiento citotóxico antes de una inmunoterapia celular
IL322309A (en)	2017-05-24	2025-09-01	Novartis Ag	IL2 antibody grafted proteins and methods of use in cancer treatment
RU2020110236A (ru) *	2017-10-26	2021-11-26	Синбиас Фарма АГ	Состав леналидомида с немедленным высвобождением
EP4272737A3 (en)	2018-04-23	2024-01-17	Celgene Corporation	Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
US10969381B2 (en) *	2018-05-23	2021-04-06	Celgene Corporation	Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
US20210317109A1 (en) *	2018-09-07	2021-10-14	Medshine Discovery Inc.	Tricyclic substituted piperidine dione compound
EP3488851A1 (en)	2018-10-03	2019-05-29	AVM Biotechnology, LLC	Immunoablative therapies
US20240216354A1 (en) *	2019-10-04	2024-07-04	Dana-Farber Cancer Institute, Inc.	Immunomodulatory imide drugs as zeta-chain-associated protein kinase 70 (zap70) agonists and uses thereof
AU2020372333A1 (en) *	2019-10-21	2022-04-28	Celgene Corporation	Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
WO2021080935A1 (en) *	2019-10-21	2021-04-29	Celgene Corporation	Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione
AU2020405129A1 (en)	2019-12-19	2022-06-23	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of androgen receptor

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3228601A (en)	1964-02-20	1966-01-11	Monarch Marking Systems Inc	Controls for marking machine
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4994443A (en)	1982-12-20	1991-02-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
US5001116A (en)	1982-12-20	1991-03-19	The Children's Medical Center Corporation	Inhibition of angiogenesis
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US5391485A (en)	1985-08-06	1995-02-21	Immunex Corporation	DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja)	1985-08-23	1988-03-10	麒麟麦酒株式会社	多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en)	1992-12-24	1994-11-01	The Whitaker Corporation	Wire retainer for current mode coupler
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
US6114355A (en)	1993-03-01	2000-09-05	D'amato; Robert	Methods and compositions for inhibition of angiogenesis
US5629327A (en)	1993-03-01	1997-05-13	Childrens Hospital Medical Center Corp.	Methods and compositions for inhibition of angiogenesis
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5798368A (en)	1996-08-22	1998-08-25	Celgene Corporation	Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US5635517B1 (en)	1996-07-24	1999-06-29	Celgene Corp	Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en)	1996-07-24	2001-08-28	Celgene Corporation	Isoindolines, method of use, and pharmaceutical compositions
PL195916B1 (pl)	1996-07-24	2007-11-30	Celgene Corp	Izomery optyczne podstawionej 1-okso-izoindoliny i 1,3-diokso-izoindoliny, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie
HU228769B1 (en)	1996-07-24	2013-05-28	Celgene Corp	Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
AU729247B2 (en)	1996-08-12	2001-01-25	Celgene Corporation	Novel immunotherapeutic agents and their use in the reduction of cytokine levels
WO1998019649A2 (en) *	1996-11-05	1998-05-14	The Children's Medical Center Corporation	Methods and compositions for inhibition of angiogenesis
US5874448A (en)	1997-11-18	1999-02-23	Celgene Corporation	Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US6020358A (en) *	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels
AU777572B2 (en) *	1999-04-01	2004-10-21	Board Of Regents, The University Of Texas System	Compositions and methods for treating lymphoma
CA2402643A1 (en) *	2000-03-17	2001-09-27	Cell Therapeutics, Inc.	Polyglutamic acid-camptothecin conjugates and methods of preparation
DE60118571T2 (de) *	2000-05-15	2007-02-01	Celgene Corp.	Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
US6458810B1 (en) *	2000-11-14	2002-10-01	George Muller	Pharmaceutically active isoindoline derivatives
JP4242651B2 (ja)	2000-11-30	2009-03-25	ザチルドレンズメディカルセンターコーポレイション	４−アミノ−サリドマイドエナンチオマーの合成法
US20030045552A1 (en)	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof
CA2752140A1 (en) *	2002-05-17	2003-11-27	Celgene Corporation	Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
US7323479B2 (en) *	2002-05-17	2008-01-29	Celgene Corporation	Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline

2003
- 2003-05-16 CA CA2752140A patent/CA2752140A1/en not_active Abandoned
- 2003-05-16 MX MXPA04011311A patent/MXPA04011311A/es active IP Right Grant
- 2003-05-16 ES ES09008756.0T patent/ES2521672T3/es not_active Expired - Lifetime
- 2003-05-16 DE DE60331537T patent/DE60331537D1/de not_active Expired - Lifetime
- 2003-05-16 EP EP09004756A patent/EP2087891A3/en not_active Withdrawn
- 2003-05-16 KR KR1020047018587A patent/KR100793564B1/ko not_active Expired - Lifetime
- 2003-05-16 CN CN2011102566053A patent/CN102302494A/zh active Pending
- 2003-05-16 SI SI200331793T patent/SI1505973T1/sl unknown
- 2003-05-16 NZ NZ563281A patent/NZ563281A/en not_active IP Right Cessation
- 2003-05-16 CA CA2752127A patent/CA2752127A1/en not_active Abandoned
- 2003-05-16 EP EP12158938.6A patent/EP2561874A3/en not_active Withdrawn
- 2003-05-16 CA CA2794297A patent/CA2794297A1/en not_active Abandoned
- 2003-05-16 CA CA2672000A patent/CA2672000C/en not_active Expired - Lifetime
- 2003-05-16 CA CA2476983A patent/CA2476983C/en not_active Expired - Lifetime
- 2003-05-16 EP EP14189022.8A patent/EP2915533B1/en not_active Revoked
- 2003-05-16 CN CN2006101504843A patent/CN1981761B/zh not_active Expired - Fee Related
- 2003-05-16 NZ NZ584663A patent/NZ584663A/en not_active IP Right Cessation
- 2003-05-16 EP EP10185504A patent/EP2316455A1/en not_active Withdrawn
- 2003-05-16 NZ NZ549175A patent/NZ549175A/en not_active IP Right Cessation
- 2003-05-16 DK DK03728969.1T patent/DK1505973T3/da active
- 2003-05-16 CA CA2727830A patent/CA2727830C/en not_active Expired - Lifetime
- 2003-05-16 NZ NZ572388A patent/NZ572388A/en not_active IP Right Cessation
- 2003-05-16 CN CN2011102561581A patent/CN102335173A/zh active Pending
- 2003-05-16 EP EP03728969A patent/EP1505973B1/en not_active Revoked
- 2003-05-16 CN CN2013103449770A patent/CN103393695A/zh not_active Withdrawn
- 2003-05-16 PT PT03728969T patent/PT1505973E/pt unknown
- 2003-05-16 KR KR1020067020849A patent/KR100822149B1/ko not_active Expired - Fee Related
- 2003-05-16 CA CA2727824A patent/CA2727824A1/en not_active Abandoned
- 2003-05-16 CN CN038168995A patent/CN1697655B/zh not_active Expired - Lifetime
- 2003-05-16 CN CN201110257161.5A patent/CN102342938B/zh not_active Expired - Lifetime
- 2003-05-16 EP EP10177056A patent/EP2272513A1/en not_active Withdrawn
- 2003-05-16 IL IL16525403A patent/IL165254A0/xx unknown
- 2003-05-16 CN CN201410690665.XA patent/CN104606193A/zh not_active Withdrawn
- 2003-05-16 ES ES03728969T patent/ES2340027T3/es not_active Expired - Lifetime
- 2003-05-16 AU AU2003234626A patent/AU2003234626B2/en not_active Expired
- 2003-05-16 CN CN201110256752.0A patent/CN102379874B/zh not_active Expired - Lifetime
- 2003-05-16 CA CA2794060A patent/CA2794060C/en not_active Expired - Lifetime
- 2003-05-16 NZ NZ536907A patent/NZ536907A/en not_active IP Right Cessation
- 2003-05-16 CN CN201310344609.6A patent/CN103494817A/zh not_active Withdrawn
- 2003-05-16 JP JP2004505051A patent/JP2005530784A/ja active Pending
- 2003-05-16 CN CN201310344594.3A patent/CN103393681B/zh not_active Expired - Lifetime
- 2003-05-16 EP EP10177041A patent/EP2272512A1/en not_active Withdrawn
- 2003-05-16 EP EP09008775A patent/EP2105136A3/en not_active Withdrawn
- 2003-05-16 CA CA2752124A patent/CA2752124A1/en not_active Abandoned
- 2003-05-16 WO PCT/US2003/015470 patent/WO2003097052A2/en not_active Ceased
- 2003-05-16 CA CA2752122A patent/CA2752122A1/en not_active Abandoned
- 2003-05-16 PT PT90087560T patent/PT2105135E/pt unknown
- 2003-05-16 EP EP09008756.0A patent/EP2105135B1/en not_active Revoked
- 2003-05-16 CN CN2011102571780A patent/CN102429908A/zh active Pending
- 2003-05-16 CN CN201310343756.1A patent/CN103495169B/zh not_active Expired - Lifetime
- 2003-05-16 AT AT03728969T patent/ATE459357T1/de active
- 2003-11-06 ZA ZA200503656A patent/ZA200503656B/xx unknown
- 2003-11-06 CN CNA2003801083980A patent/CN1735415A/zh active Pending
2004
- 2004-11-16 IL IL165254A patent/IL165254A/en active IP Right Grant
- 2004-11-22 ZA ZA200409388A patent/ZA200409388B/xx unknown
- 2004-11-22 ZA ZA200409387A patent/ZA200409387B/en unknown
2006
- 2006-10-19 IL IL178747A patent/IL178747A/en active IP Right Grant
- 2006-10-19 IL IL178748A patent/IL178748A/en active IP Right Grant
- 2006-10-19 IL IL178746A patent/IL178746A0/en unknown
- 2006-10-19 IL IL178745A patent/IL178745A/en active Protection Beyond IP Right Term
- 2006-10-24 JP JP2006288966A patent/JP2007008966A/ja active Pending
2009
- 2009-05-13 JP JP2009116367A patent/JP5839770B2/ja not_active Expired - Lifetime
- 2009-05-13 JP JP2009116363A patent/JP2009191072A/ja not_active Withdrawn
- 2009-05-26 IL IL198978A patent/IL198978A/en active IP Right Grant
2010
- 2010-04-23 CY CY20101100363T patent/CY1110013T1/el unknown
2012
- 2012-05-10 IL IL219732A patent/IL219732A0/en unknown
- 2012-12-14 JP JP2012273326A patent/JP5830005B2/ja not_active Expired - Lifetime
2013
- 2013-02-28 JP JP2013038222A patent/JP2013126999A/ja not_active Withdrawn
2014
- 2014-11-27 CY CY20141100987T patent/CY1115782T1/el unknown
2015
- 2015-01-27 LU LU92642C patent/LU92642I2/xx unknown
- 2015-02-06 CY CY2015003C patent/CY2015003I2/el unknown
- 2015-06-23 JP JP2015125342A patent/JP6194335B2/ja not_active Expired - Lifetime
2016
- 2016-03-22 IL IL244727A patent/IL244727A0/en unknown
2017
- 2017-05-12 JP JP2017095838A patent/JP2017132817A/ja active Pending

Also Published As

Publication number	Publication date
ES2521672T3 (es)	2014-11-13
ATE459357T1 (de)	2010-03-15
CY1110013T1 (el)	2015-01-14
CA2794297A1 (en)	2003-11-27
NZ584663A (en)	2011-09-30
CA2752127A1 (en)	2003-11-27
ES2340027T3 (es)	2010-05-28
EP1505973A2 (en)	2005-02-16
JP2009191072A (ja)	2009-08-27
PT2105135E (pt)	2015-02-06
CY1115782T1 (el)	2015-12-09
JP2009173683A (ja)	2009-08-06
EP2105136A3 (en)	2010-01-27
EP2105136A2 (en)	2009-09-30
CN1697655B (zh)	2013-09-18
IL178746A0 (en)	2007-02-11
CN102429908A (zh)	2012-05-02
ZA200409388B (en)	2006-05-31
IL178745A (en)	2012-06-28
CN103393681B (zh)	2017-04-12
CA2672000C (en)	2011-11-29
JP5830005B2 (ja)	2015-12-09
EP1505973A4 (en)	2006-05-17
IL178748A0 (en)	2007-02-11
ZA200503656B (en)	2009-02-25
EP2105135A3 (en)	2010-02-10
CN1697655A (zh)	2005-11-16
EP2272512A1 (en)	2011-01-12
CN104606193A (zh)	2015-05-13
CN1735415A (zh)	2006-02-15
LU92642I2 (fr)	2015-04-24
JP2013126999A (ja)	2013-06-27
HK1072180A1 (en)	2005-08-19
EP2316455A1 (en)	2011-05-04
CN103494817A (zh)	2014-01-08
JP2017132817A (ja)	2017-08-03
CA2672000A1 (en)	2003-11-27
NZ572388A (en)	2010-05-28
JP2005530784A (ja)	2005-10-13
EP2915533B1 (en)	2017-09-13
CA2727824A1 (en)	2003-11-27
PT1505973E (pt)	2010-05-21
NZ549175A (en)	2007-12-21
CN102335173A (zh)	2012-02-01
IL165254A (en)	2013-03-24
AU2003234626A1 (en)	2003-12-02
JP2013049734A (ja)	2013-03-14
EP2087891A2 (en)	2009-08-12
NZ536907A (en)	2006-10-27
EP2915533A1 (en)	2015-09-09
CN1981761B (zh)	2011-10-12
CA2794060C (en)	2017-08-22
EP2087891A3 (en)	2010-01-27
CN102379874B (zh)	2016-08-17
WO2003097052A2 (en)	2003-11-27
DE60331537D1 (de)	2010-04-15
CA2727830A1 (en)	2003-11-27
KR20050010815A (ko)	2005-01-28
CA2476983A1 (en)	2003-11-27
DK1505973T3 (da)	2010-05-31
CN103393681A (zh)	2013-11-20
IL178745A0 (en)	2007-02-11
CA2752124A1 (en)	2003-11-27
EP2561874A3 (en)	2013-09-04
JP2015187156A (ja)	2015-10-29
CN103393695A (zh)	2013-11-20
IL178748A (en)	2013-10-31
HK1104968A1 (en)	2008-02-01
CN102302494A (zh)	2012-01-04
CN103495169B (zh)	2016-06-22
KR100793564B1 (ko)	2008-01-14
EP2561874A2 (en)	2013-02-27
NZ563281A (en)	2009-05-31
EP2272513A1 (en)	2011-01-12
ZA200409387B (en)	2006-06-28
IL165254A0 (en)	2005-12-18
HK1134019A1 (en)	2010-04-16
JP6194335B2 (ja)	2017-09-06
AU2003234626B2 (en)	2006-03-09
CA2752140A1 (en)	2003-11-27
KR20060110014A (ko)	2006-10-23
EP1505973B1 (en)	2010-03-03
EP2105135B1 (en)	2014-10-22
CY2015003I1 (el)	2015-12-09
CA2476983C (en)	2011-01-25
CA2794060A1 (en)	2003-11-27
CN102342938B (zh)	2014-08-20
WO2003097052A3 (en)	2003-12-18
KR100822149B1 (ko)	2008-04-15
CA2752122A1 (en)	2003-11-27
JP5839770B2 (ja)	2016-01-06
AU2003234626C1 (en)	2003-12-02
CN102342938A (zh)	2012-02-08
IL219732A0 (en)	2012-06-28
CN103495169A (zh)	2014-01-08
IL198978A (en)	2011-08-31
CN102379874A (zh)	2012-03-21
CY2015003I2 (el)	2015-12-09
JP2007008966A (ja)	2007-01-18
IL178747A0 (en)	2007-02-11
CN1981761A (zh)	2007-06-20
MXPA04011311A (es)	2005-02-14
IL244727A0 (en)	2016-05-01
IL178747A (en)	2015-06-30
EP2105135A2 (en)	2009-09-30
CA2727830C (en)	2014-09-16

Publication	Publication Date	Title
SI1505973T1 (sl)	2010-06-30	Kombinacija za zdravljenje multiplega mieloma
WO2004103274A3 (en)	2005-03-03	Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2004043377A3 (en)	2004-08-05	Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2005046593A3 (en)	2006-03-02	Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
MX2007005570A (es)	2007-07-09	Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
WO2004043378A3 (en)	2004-09-02	Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
UA94097C2 (ru)	2011-04-11	Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
WO2005002582A3 (en)	2005-05-26	Trp-p8 active compounds and therapeutic treatment methods
MY148480A (en)	2013-04-30	Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MX2009001130A (es)	2009-05-13	Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos.
MX2010005009A (es)	2010-05-27	Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.
WO2006032525A3 (en)	2006-05-04	Combinational therapy for treating cancer
MX2024005997A (es)	2024-08-09	Antagonistas del receptor de adenosina.
UA84566C2 (ru)	2008-11-10	Производные тиофенпиримидинонов и их применение в терапии, фармацевтическая композиция на их основе